Regeneron

Regeneron Pharmaceuticals, Inc. is a prominent American biotechnology company based in Tarrytown, New York. Founded in 1988 by Nobel laureate Alfred G. Gilman and others, Regeneron focuses on the development of innovative medicines for serious diseases. The company operates as a fully integrated biopharmaceutical enterprise, engaging in research, development, manufacturing, and commercialization of its products. Regeneron is well-known for its advanced biologics, including monoclonal antibodies and VEGF-traps. Its key products address various medical conditions, such as EYLEA for eye diseases, Dupixent for immunology, and Libtayo for oncology. The company employs over 10,000 people and has a global presence with facilities in North America, Europe, Asia, and Australia. Regeneron collaborates with major pharmaceutical partners to enhance its research and distribution capabilities, aiming to meet unmet medical needs across multiple therapeutic areas.